Altimmune to Participate in Two Upcoming Investor Conferences
Provided By GlobeNewswire
Last update: Nov 5, 2025
GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for one-on-one meetings at the following investor conferences:
Read more at globenewswire.com
